Kolma BioTech Decides to Absorb Wholly-Owned Subsidiary MOD Materials via Zero-Capital Merger, No New Shares Issued Thus No Dilution for Existing Shareholders

Kolma BioTech resolved on July 20, 2026 to absorb its wholly-owned subsidiary MOD Materials at a merger ratio of 1:0. The merger is a zero-capital increase with no new shares issued, resulting in zero dilution for existing shareholders.
The merger aims to integrate business capabilities and enhance operational efficiency by consolidating infrastructure and leveraging Kolma Group resources, leading to cost savings and profitability improvement. It is expected to diversify stable revenue streams and improve earnings per share, ultimately enhancing shareholder value.
As a small-scale merger, shareholder approval is replaced by board resolution, and no appraisal rights are granted. However, if shareholders holding 20% or more of outstanding shares object within two weeks of the merger notice, the merger process may be altered.
[AI Summary]Kolma BioTech's absorption of its wholly-owned subsidiary without issuing new shares poses no dilution risk to existing shareholders. While synergy and operational efficiency gains are anticipated, the target's recent net loss and high debt ratio are short-term financial concerns. In the mid-to-long term, resource integration may improve profitability and positively impact shareholder value.